Coya Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow-4.93%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for COYA is -4.93%. That is below the sector sector average of 11.85%. Investors often review this figure alongside Coya Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, COYA currently prints -4.93% for ROE, while the sector average sits near 11.85%. That is roughly 141.6% below the sector mean. Large gaps often invite a closer look at Coya Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Coya Therapeutics converts resources into returns. At -4.93%, COYA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting COYA's ROE (-4.93%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
